Cash Flow Statement

Amortizatization of Intangibles Asset Writedowns and Impairment Cash from Financing Activities Cash from Investing Activities Cash from Operations Change in Account Payables Change in Accured Expenses Change in Cash Deferred Taxes Free Cash Flow Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Income Non-cash Items Other Working Capital Changes Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Pelthos Therapeutics (PTHS) Deferred Taxes (2025)

Pelthos Therapeutics has reported Deferred Taxes over the past 1 years, most recently at $7.9 million for Q4 2025.